Cases & Deals

TxCell completes €11 million rights issue

Clients TxCell SA

Jones Day advised TxCell SA, a biotech company specializing in innovative, personalized cell-based immunotherapies, and Invest Securities, as lead manager and bookrunner, in connection with the €11 million (US$11.6 million) rights issue of new shares with warrants attached.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.